GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » ROE %

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) ROE % : -86.61% (As of Dec. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sunesis Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2020 was $-19.23 Mil. Sunesis Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2020 was $22.20 Mil. Therefore, Sunesis Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2020 was -86.61%.

The historical rank and industry rank for Sunesis Pharmaceuticals's ROE % or its related term are showing as below:

SNSS's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.085
* Ranked among companies with meaningful ROE % only.

Sunesis Pharmaceuticals ROE % Historical Data

The historical data trend for Sunesis Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals ROE % Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -157.06 -166.59 -208.44 -147.96 -91.03

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.69 -93.09 -133.85 -91.45 -86.61

Competitive Comparison of Sunesis Pharmaceuticals's ROE %

For the Biotechnology subindustry, Sunesis Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's ROE % falls into.



Sunesis Pharmaceuticals ROE % Calculation

Sunesis Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-21.61/( (27.543+19.937)/ 2 )
=-21.61/23.74
=-91.03 %

Sunesis Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2020 is calculated as

ROE %=Net Income (Q: Dec. 2020 )/( (Total Stockholders Equity (Q: Sep. 2020 )+Total Stockholders Equity (Q: Dec. 2020 ))/ count )
=-19.228/( (24.466+19.937)/ 2 )
=-19.228/22.2015
=-86.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2020) net income data. ROE % is displayed in the 30-year financial page.


Sunesis Pharmaceuticals  (NAS:SNSS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2020 )
=Net Income/Total Stockholders Equity
=-19.228/22.2015
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-19.228 / 0)*(0 / 25.64)*(25.64 / 22.2015)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1549
=ROA %*Equity Multiplier
=N/A %*1.1549
=-86.61 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2020 )
=Net Income/Total Stockholders Equity
=-19.228/22.2015
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-19.228 / -19.228) * (-19.228 / -22.752) * (-22.752 / 0) * (0 / 25.64) * (25.64 / 22.2015)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8451 * N/A % * 0 * 1.1549
=-86.61 %

Note: The net income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Sunesis Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Executives
Steve Carchedi director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto director 58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum director 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young director
Homer L Pearce director 84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt director, officer: See Remarks C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump director
Tina Gullotta officer: VP, Finance SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Headlines

From GuruFocus

Sunesis Announces Pricing of $12 Million Offering of Common Stock

By Marketwired Marketwired 07-29-2020